PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  2009-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/ATVBAHA.109.194191PMID 19762784
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A new method for measurement of total plasma PCSK9: clinical applications

  2010cited by this paper
• A new method for measurement of total plasma PCSK 9 : clinical applications

  2009cited by this paper
• Genetic and metabolic determinants of plasma PCSK9 levels.

  2009cited by this paper
• Molecular basis for LDL receptor recognition by PCSK9

  2008cited by this paper
• Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population.

  2008cited by this paper
• PCSK9 and LDL cholesterol: unravelling the target to design the bullet.

  2008cited by this paper
• Molecular diagnosis of hypobetalipoproteinemia: an ENID review.

  2007cited by this paper
• [Familial hypobetalipoproteinemia].

  2007cited by this paper
• Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.

  2007cited by this paper
• A Novel Loss of Function Mutation of PCSK9 Gene in White Subjects With Low-Plasma Low-Density Lipoprotein Cholesterol

  2007cited by this paper
• PPARγ and human metabolic disease

  2006cited by this paper
• Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

  2006cited by this paper
• Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy

  2006cited by this paper
• The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6A

  2006cited by this paper
• Abstract 340: The C679X Mutation in PCSK9 is Present and Lowers Blood Cholesterol in a Southern African Population

  2006cited by this paper
• Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.

  2006cited by this paper
• PPAR gamma and human metabolic disease.

  2006cited by this paper
• Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

  2006cited by this paper
• Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c*

  2006cited by this paper
• Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia

  2005cited by this paper
• Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia.

  2005cited by this paper
• Monogenic Hypocholesterolaemic Lipid Disorders and Apolipoprotein B Metabolism

  2005cited by this paper
• Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

  2005cited by this paper
• High frequency of APOB gene mutations causing familial hypobetalipoproteinaemia in patients of Dutch and Spanish descent

  2005cited by this paper
• The low-density lipoprotein receptor is regulated by estrogen and forms a functional complex with the estrogen-regulated protein ezrin in pituitary GH3 somatolactotropes.

  2004cited by this paper
• Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations in PCSK9

  2004cited by this paper
• Functional characterization of Narc 1, a novel proteinase related to proteinase K.

  2003cited by this paper
• Familial hypobetalipoproteinemia Published, JLR Papers in Press, March 16, 2003. DOI 10.1194/jlr.R300002-JLR200

  2003cited by this paper
• Effect of Atorvastatin on Apolipoprotein B100 Containing Lipoprotein Metabolism in Type-2 Diabetes

  2003cited by this paper
• Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

  2003cited by this paper
• Intronic mutations outside of Alu-repeat-rich domains of the LDL receptor gene are a cause of familial hypercholesterolemia

  2002cited by this paper
• The role of the LDL receptor in apolipoprotein B secretion.

  2000cited by this paper
• Metabolic abnormalities of apolipoprotein B‐containing lipoproteins in non‐insulin‐dependent diabetes: a stable isotope kinetic study

  2000cited by this paper
• Development of compartmental models in stable-isotope experiments: application to lipid metabolism.

  1998cited by this paper
• Protein memory through altered folding mediated by intramolecular chaperones

  1997cited by this paper
• Immortalized human hepatocytes as a tool for the study of hepatocytic (de-)differentiation

  1997cited by this paper
• Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes.

  1997cited by this paper
• Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism.

  1992cited by this paper
• Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus.

  1984cited by this paper
• Blood volume measurement: a critical study prediction of normal values: controlled measurement of sequential changes: choice of a bedside method.

  1965cited by this paper

• Impact of loss-of-function variations of PCSK9 on LDLR interaction and dynamics: Implications for heart function.

  2026cites this paper
• The Role of Lipids in Atherosclerosis: Focus on Molecular Biology Mechanisms and Therapeutic Approaches.

  2025cites this paper
• Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside

  2024cites this paper
• Keeping translational research grounded in human biology

  2024cites this paper
• PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes

  2024cites this paper
• Unraveling Estrogen and PCSK9’s Roles in Lipid Metabolism Disorders among Ovariectomized Mice

  2024cites this paper
• The role of PCSK9 in heart failure and other cardiovascular diseases—mechanisms of action beyond its effect on LDL cholesterol

  2024cites this paper
• SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2

  2023cites this paper
• Targeting PCSK9 to tackle cardiovascular disease.

  2023cites this paper
• Novel protein-truncating variant in the APOB gene may protect from coronary artery disease and adverse cardiovascular events

  2022influential citation
• Inclisiran: How Widely and When Should We Use It?

  2022cites this paper
• The Emerging Roles of Intracellular PCSK9 and Their Implications in Endoplasmic Reticulum Stress and Metabolic Diseases

  2022cites this paper
• Familial hypobetalipoproteinemia caused by homozygous loss-of-function mutations in PCSK9: A case report.

  2022cites this paper
• Rosa26-LSL-dCas9-VPR: a versatile mouse model for tissue specific and simultaneous activation of multiple genes for drug discovery

  2022cites this paper
• PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation

  2021cites this paper
• PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs

  2021cites this paper
• Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice.

  2021cites this paper
• The PCSK9 Involves in the Dyslipidemia of Ovariectomized Mice and Its Mechanism

  2021cites this paper
• Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol

  2021cites this paper
• New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects

  2021cites this paper
• The Multifaceted Biology of PCSK9

  2021influential citation
• VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly

  2020cites this paper
• Rare Diseases Related with Lipoprotein Metabolism.

  2020cites this paper
• Lipoprotein disorders

  2020cites this paper
• Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia

  2020cites this paper
• Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis.

  2020cites this paper
• Functional analysis of natural PCSK9 mutants in modern and archaic humans

  2020cites this paper
• Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy

  2020cites this paper
• A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene

  2020cites this paper
• Phenotypic Differences Between Polygenic and Monogenic Hypobetalipoproteinemia

  2020cites this paper
• The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease

  2020cites this paper
• Hypobêtalipoprotéinémies génétiques. Maladie de rétention des chylomicrons, abêtalipoprotéinémie, hypobêtalipoprotéinémies familiales et hypolipidémie combinée familiale

  2020cites this paper
• PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis

  2020cites this paper
• PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease

  2019cites this paper
• The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function.

  2019cites this paper
• N-Glycosylation Defects in Man Lower LDL-Cholesterol Through Increased LDL Receptor Expression.

  2019cites this paper
• N-Glycosylation Defects in Man Lower LDL-Cholesterol Through Increased LDL Receptor Expression

  2019cites this paper
• Métabolisme des lipides et des lipoprotéines chez l’homme

  2019cites this paper
• Type 2 diabetes-associated single nucleotide polymorphism in Sorcs1 gene results in alternative processing of the Sorcs1 protein in INS1 β-cells

  2019cites this paper
• Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents

  2019cites this paper
• N-Glycosylation Defects in Humans Lower Low-Density Lipoprotein Cholesterol Through Increased Low-Density Lipoprotein Receptor Expression

  2019cites this paper
• Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies

  2019cites this paper
• Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies.

  2018cites this paper
• Genetic functional studies of low density lipoprotein-cholesterol (LDL-C) associated variants and the genetic spectrum of familial hypercholesterolemia in different ethnic groups

  2018cites this paper
• Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?

  2018cites this paper
• Inhibiting PCSK9 — biology beyond LDL control

  2018cites this paper
• Prevalence of hypobetalipoproteinemia and related psychiatric characteristics in a psychiatric population: results from the retrospective HYPOPSY Study

  2018cites this paper
• Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?

  2018cites this paper
• Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?

  2018cites this paper
• Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.

  2018cites this paper
• Unpacking and Understanding the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Apolipoprotein B Metabolism

  2017cites this paper
• Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.

  2017cites this paper
• Evolocumab for the treatment of hypercholesterolemia

  2017cites this paper
• Low-Density Lipoprotein Cholesterol (LDL-C): How Low?

  2017cites this paper
• Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism

  2017cites this paper
• Can LDL cholesterol be too low? Possible risks of extremely low levels

  2017cites this paper
• Lipid Lowering Therapy and Circulating PCSK9 Concentration

  2017cites this paper
• A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.

  2017cites this paper
• PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans

  2017cites this paper
• The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9

  2017cites this paper
• Complexity of mechanisms among human proprotein convertase subtilisin–kexin type 9 variants

  2017influential citation
• Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes.

  2017cites this paper
• Hypercholesterolemia: The role of PCSK9.

  2017cites this paper
• Packard, C. J. (2017) Unpacking and understanding the impact of proprotein convertase subtilisin/kexin type 9 inhibitors on apolipoprotein B

  2017cites this paper
• The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.

  2017cites this paper
• Update on the molecular biology of dyslipidemias.

  2016cites this paper
• Independent Link Between Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and FABP4 in a General Population Without Medication.

  2016cites this paper
• Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.

  2016cites this paper
• Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima–media thickness in hypertensives

  2016cites this paper
• Lower the low-density lipoprotein cholesterol to the level when you born

  2016cites this paper
• New developments in proprotein convertase subtilisin–kexin 9's biology and clinical implications

  2016cites this paper
• Using human genetics to discover new therapeutic targets for plasma lipids

  2016cites this paper
• Structure-function analyses of microsomal triglyceride transfer protein missense mutations in abetalipoproteinemia and hypobetalipoproteinemia subjects.

  2016cites this paper
• Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.

  2016cites this paper
• Disadvantages of Current LDL-cholesterol Lowering and the Role of PCSK 9 Inhibitors 4

  2016cites this paper
• Integration of Clinical Genetic Testing in Cardiovascular Care

  2016influential citation
• Potential of PCSK9 as a new target for the management of LDL cholesterol

  2015cites this paper
• New and Emerging Therapies for Hyperlipidemia

  2015cites this paper
• 1 PCSK 9 deficiency unmasks a sex / tissue-specific subcellular distribution of the LDL and VLDL receptors in mice

  2015cites this paper
• Understanding PCSK9 and anti-PCSK9 therapies.

  2015cites this paper
• PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice[S]

  2015cites this paper
• Prevention PCSK 9 ( Proprotein convertase subtilisin / kexin type 9 ) inhibitors : past , present , and the future

  2015cites this paper
• PCSK9 Inhibition: Current Concepts and Lessons from Human Genetics

  2015cites this paper
• PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.

  2015cites this paper
• PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.

  2015cites this paper
• Potential of PCSK9 as a new target for the management of LDL cholesterol

  2015cites this paper
• New developments in atherosclerosis : clinical potential of PCSK 9 inhibition ilaria

  2015cites this paper
• Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes.

  2015cites this paper
• The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol

  2015cites this paper
• The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans.

  2015cites this paper
• Role of PCSK9 beyond liver involvement

  2015cites this paper
• PCSK9 and its modulation.

  2015cites this paper
• PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges.

  2014cites this paper
• Preserved adrenal function in fully PCSK9-deficient subject.

  2014cites this paper
• Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S]

  2014cites this paper
• Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease

  2014cites this paper
• Update on Primary Hypobetalipoproteinemia

  2014cites this paper
• Targeting PCSK9 for hypercholesterolemia.

  2014cites this paper
• Lipid lowering with PCSK9 inhibitors

  2014cites this paper
• Novel biomarkers, cardiovascular disease and diabetic chronic kidney disease

  2014cites this paper